Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) shares saw unusually-strong trading volume on Monday . Approximately 4,150,568 shares were traded during mid-day trading, an increase of 68% from the previous session’s volume of 2,469,988 shares.The stock last traded at $5.05 and had previously closed at $4.99.

A number of equities analysts recently commented on SGYP shares. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Synergy Pharmaceuticals in a research note on Thursday, April 21st. Roth Capital reaffirmed a “buy” rating on shares of Synergy Pharmaceuticals in a research note on Monday, May 9th. BTIG Research reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Synergy Pharmaceuticals in a research note on Tuesday, April 19th. Canaccord Genuity reissued a “buy” rating and set a $13.00 target price on shares of Synergy Pharmaceuticals in a research note on Monday, May 23rd. Finally, Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Monday, May 16th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Synergy Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $10.37.

The firm’s market cap is $908.00 million. The firm’s 50-day moving average price is $4.10 and its 200-day moving average price is $3.56.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.03. Analysts forecast that Synergy Pharmaceuticals Inc. will post ($1.03) earnings per share for the current fiscal year.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.